Olygose is pleased to announce that its range of ingredients has been granted two new health claims in the European Union following the public
Products containing Olygose alpha-galacto-oligosaccharides in replacement of sugar or fermentable carbohydrates will be allowed to use the following health claims :
Olygose received a favourable opinion from European Food Safety Authority (EFSA) on an article 13(5) claim application back in 2014, supporting the effect of alpha-galacto-oligosaccharides on the lowering of glycemic response (EFSA Journal 2014;12(10):3838).
This approval highlights the health claim-focused approach of Olygose since its inception in 2009 and rewards important market-oriented R&D efforts.
Olygose develops and produces a range of patented innovative ingredients extracted from various dietary plant-based raw materials. Its headquarters and demonstration plant are located 70 km North of Paris in the heart of the Compiègne/Venette greentech cluster since its set-up in 2009.
Its soluble proprietary prebiotic fibres have unique taste and processing characteristics and clinically proven advantages in healthy food, notably in the areas of satiety as well as metabolic syndrome but also in infant nutrition.
Olygose’s clinical programmes are based on recent demonstrations of the role of intestinal microbiota in health and diseases, notably by the teams of Professor Karine Clément at the Institute of Cardiometabolism And Nutrition (ICAN) / Pitié Salpétrière Hospital in Paris.